Table 3– Long-term (24 month) treatment outcomes after treatment with delamanid in combination with an optimised background treatment regimen: XDR-TB patients only
Treatment outcomeLong-term treatment#Short-term treatmentAll Patients+
Favourable27 (61.4; 45.5–75.6)6 (50.0; 21.1–78.9)33 (58.9; 45.0–71.9)
Cured11 (25.0; 13.2–40.3)5 (41.7; 15.2–72.3)16 (28.6; 17.3–42.2)
Completed16 (36.4; 22.4–52.2)1 (8.3; 0.2–38.5)17 (30.4; 18.8–44.1)
Unfavourable17 (38.6; 24.4–54.5)6 (50.0; 21.1–78.9)23 (41.1; 28.1–55.0)
Died0 (0.0)§3 (25.0; 5.5–57.2)§3 (5.4; 1.1–14.9)
Failed14 (31.8; 18.6–47.6)3 (25.0; 5.5–57.2)17 (30.4; 18.8–44.1)
Defaulted3 (6.8; 1.4–18.7)0.0 (0.0)3 (5.4; 1.1–14.9)
  • Data are presented as n (%; 95% CI). XDR-TB: extensively drug-resistant tuberculosis. #: 44 patients received delamanid (100 mg and/or 200 mg twice a day) for at least 6 months; : 12 patients received delamanid (100 mg or 200 mg twice a day) or placebo for 2 months; +: n=56; §: differences between the long-term and the short-term treatment groups for the corresponding treatment outcome were statistically significant (p<0.001), all other differences did not reach statistical significance (p≥0.05).